A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation

BACKGROUND: In a phase 3 trial, letermovir reduced clinically significant cytomegalovirus infections (CS-CMVi) and all-cause mortality at week 24 versus placebo in CMV-seropositive allogeneic hematopoietic cell transplantation (HCT) recipients. This post hoc analysis of phase 3 data further investig...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Infect Dis
Auteurs principaux: Ljungman, Per, Schmitt, Michael, Marty, Francisco M, Maertens, Johan, Chemaly, Roy F, Kartsonis, Nicholas A, Butterton, Joan R, Wan, Hong, Teal, Valerie L, Sarratt, Kendra, Murata, Yoshihiko, Leavitt, Randi Y, Badshah, Cyrus
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2020
Sujets:
Articles and Commentaries
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7146004/
https://ncbi.nlm.nih.gov/pubmed/31179485
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/ciz490
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires